Loading
SCN8A (Sodium channel protein type 8 subunit alpha) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Non-small-cell lung cancer.
Pore-forming subunit of a voltage-gated sodium channel complex assuming opened or closed conformations in response to the voltage difference across membranes and through which sodium ions selectively pass along their electrochemical gradient. Contributes to neuronal excitability by regulating action potential threshold and propagation. More specifically expressed in non-neuronal cells, could play a role in sodium release from intracellular compartments and participate in the control of podosomes formation and macrophages adhesion and movement.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Pembrolizumab. Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.91, animal model 0.57, genetic association 0.00, clinical 0.86).
In plain words · SCN8A (Sodium channel protein type 8 subunit alpha) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Non-small-cell lung cancer.
SCN8A (Sodium channel protein type 8 subunit alpha) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Non-small-cell lung cancer.
Pore-forming subunit of a voltage-gated sodium channel complex assuming opened or closed conformations in response to the voltage difference across membranes and through which sodium ions selectively pass along their electrochemical gradient.
No product in this corpus aims at SCN8A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA SCN8A: RNA group enriched (brain 17 nTPM, pituitary gland 6 nTPM, retina 7 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas SCN8A tissue; Open Targets ENSG00000196876 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Plummer N.W. et al, J. Biol. Chem, 1997, "Alternative splicing of the sodium channel SCN8A predicts a truncated two-domain protein in fetal brain and non-neuronal cells". Source.
Sources: HGNC HGNC:10596 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UQD0 (protein name, function text, keywords and locations (REST API)); CIViC gene SCN8A (1 evidence items, 0 assertions, 1 variants; diseases: Lung Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000196876 (association with cancer (MONDO_0004992) 0.56; (GraphQL API, CC0))
Pore-forming subunit of a voltage-gated sodium channel complex assuming opened or closed conformations in response to the voltage difference across membranes and through which sodium ions selectively pass along their electrochemical gradient. Contributes to neuronal excitability by regulating action potential threshold and propagation. More specifically expressed in non-neuronal cells, could play a role in sodium release from intracellular compartments and participate in the control of podosomes formation and macrophages adhesion and movement. Location: Cell membrane; Cell projection, axon; Cytoplasmic vesicle; Cell projection, podosome (UniProt). Locus 12q13.13 (HGNC).
RNA: group enriched (brain 17 nTPM, pituitary gland 6 nTPM, retina 7 nTPM), detected in some normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA SCN8A tissue · HPA SCN8A pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SCN8A" OR ABSTRACT:"SCN8A" OR TITLE:"sodium voltage-gated channel alpha subunit 8" OR ABSTRACT:"sodium voltage-gated channel alpha subunit 8" OR TITLE:"Sodium channel protein type 8 subunit alpha" OR ABSTRACT:"Sodium channel protein type 8 subunit alpha" OR TITLE:"Nav1.6" OR ABSTRACT:"Nav1.6" OR TITLE:"NaCh6" OR ABSTRACT:"NaCh6" OR TITLE:"PN4" OR ABSTRACT:"PN4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SCN8A, not a curated reading list.